Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jimmy Ruiz

Showing results (21-30 of 99) with videos related to

Pageof 10
Sort By:
Oncogene|April 24, 2022
Exosomal miR-4466 from nicotine-activated neutrophils promotes tumor cell stemness and metabolism in lung cancer metastasisAbhishek Tyagi, Shih-Ying Wu, Sambad Sharma, et al.
Neoplasia (New York, N.Y.)|December 13, 2024
Identification of TUBB3 as an immunotherapy target in lung cancer by genome wide in vivo CRISPR screeningDan Zhao, Ravindra Deshpande, Kerui Wu, et al.
Cancers|September 14, 2024
Deep Learning Model for Predicting Lung Adenocarcinoma Recurrence from Whole Slide ImagesZiyu Su, Usman Afzaal, Shuo Niu, et al.
Oncogene|January 9, 2025
Retraction Note: Exosomal miR-4466 from nicotine-activated neutrophils promotes tumor cell stemness and metabolism in lung cancer metastasisAbhishek Tyagi, Shih-Ying Wu, Sambad Sharma, et al.
Molecular Cancer|April 14, 2018
Favorable outcome of patients with lung adenocarcinoma harboring POLE mutations and expressing high PD-L1Liang Liu, Jimmy Ruiz, Stacey S O'Neill, et al.
Oncology Letters|January 19, 2019
Circulating immune biomarkers as predictors of the response to pembrolizumab and weekly low dose carboplatin and paclitaxel in NSCLC and poor PS: An interim analysisMarcelo Bonomi, Tamjeed Ahmed, Safoa Addo, et al.
ACS Biomaterials Science & Engineering|November 15, 2019
Pleural Effusion Aspirate for use in 3D Lung Cancer Modeling and Chemotherapy ScreeningAndrea Mazzocchi, Mahesh Devarasetty, Samuel Herberg, et al.
Clinical Lung Cancer|February 25, 2020
Performance Status and Age as Predictors of Immunotherapy Outcomes in Advanced Non-Small-Cell Lung CancerTamjeed Ahmed, Thomas Lycan, Andy Dothard, et al.
Plos One|October 13, 2016
A Phase II Clinical Trial of CPI-613 in Patients with Relapsed or Refractory Small Cell Lung CarcinomaThomas W Lycan, Timothy S Pardee, William J Petty, et al.
Journal of the American College of Surgeons|January 30, 2016
Prognostic Molecular Subtypes of Low-Grade Cancer of the AppendixEdward A Levine, Konstantinos I Votanopoulos, Shadi A Qasem, et al.
Pageof 10

Showing results (21-30 of 99) with videos related to

Sort By:
Pageof 10
Oncogene|April 24, 2022
Exosomal miR-4466 from nicotine-activated neutrophils promotes tumor cell stemness and metabolism in lung cancer metastasisAbhishek Tyagi, Shih-Ying Wu, Sambad Sharma, et al.
Neoplasia (New York, N.Y.)|December 13, 2024
Identification of TUBB3 as an immunotherapy target in lung cancer by genome wide in vivo CRISPR screeningDan Zhao, Ravindra Deshpande, Kerui Wu, et al.
Cancers|September 14, 2024
Deep Learning Model for Predicting Lung Adenocarcinoma Recurrence from Whole Slide ImagesZiyu Su, Usman Afzaal, Shuo Niu, et al.
Oncogene|January 9, 2025
Retraction Note: Exosomal miR-4466 from nicotine-activated neutrophils promotes tumor cell stemness and metabolism in lung cancer metastasisAbhishek Tyagi, Shih-Ying Wu, Sambad Sharma, et al.
Molecular Cancer|April 14, 2018
Favorable outcome of patients with lung adenocarcinoma harboring POLE mutations and expressing high PD-L1Liang Liu, Jimmy Ruiz, Stacey S O'Neill, et al.
Oncology Letters|January 19, 2019
Circulating immune biomarkers as predictors of the response to pembrolizumab and weekly low dose carboplatin and paclitaxel in NSCLC and poor PS: An interim analysisMarcelo Bonomi, Tamjeed Ahmed, Safoa Addo, et al.
ACS Biomaterials Science & Engineering|November 15, 2019
Pleural Effusion Aspirate for use in 3D Lung Cancer Modeling and Chemotherapy ScreeningAndrea Mazzocchi, Mahesh Devarasetty, Samuel Herberg, et al.
Clinical Lung Cancer|February 25, 2020
Performance Status and Age as Predictors of Immunotherapy Outcomes in Advanced Non-Small-Cell Lung CancerTamjeed Ahmed, Thomas Lycan, Andy Dothard, et al.
Plos One|October 13, 2016
A Phase II Clinical Trial of CPI-613 in Patients with Relapsed or Refractory Small Cell Lung CarcinomaThomas W Lycan, Timothy S Pardee, William J Petty, et al.
Journal of the American College of Surgeons|January 30, 2016
Prognostic Molecular Subtypes of Low-Grade Cancer of the AppendixEdward A Levine, Konstantinos I Votanopoulos, Shadi A Qasem, et al.
Pageof 10